Acurx Pharmaceuticals, Inc. (ACXP) Stock
ACXP Key Statistics
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
CEO: David Luci. Company website
ACXP — Frequently Asked Questions
What is the ACXP stock price today?
Acurx Pharmaceuticals, Inc. (ACXP) trades at $2.42, down 21.94% on the day, as of Nov 12, 2026 10:46 UTC.
What is Acurx Pharmaceuticals, Inc.'s market cap?
Acurx Pharmaceuticals, Inc. has a market capitalisation of $3.84M, calculated from the live ACXP share price and shares outstanding.
What is the P/E ratio of ACXP?
ACXP has no meaningful price-to-earnings ratio: Acurx Pharmaceuticals, Inc. lost $5.93 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Acurx Pharmaceuticals, Inc. make?
Acurx Pharmaceuticals, Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for ACXP?
ACXP has traded between $1.33 and $7.54 over the past 52 weeks, and the last price is 67.9% below that high.
Is Acurx Pharmaceuticals, Inc. profitable?
Yes. Acurx Pharmaceuticals, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for ACXP?
Wall Street analysts rate ACXP Buy.
What sector is Acurx Pharmaceuticals, Inc. in?
Acurx Pharmaceuticals, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Acurx Pharmaceuticals, Inc.?
David Luci is the chief executive of Acurx Pharmaceuticals, Inc., which employs 4 people.
Where can I track ACXP in real time?
QFI Terminal shows ACXP with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ACXP live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ACXP in Terminal See plans